Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial

Kevin Kalinsky; Melissa Accordino; Codruța Chiuzan; Prabhjot S. Mundi; Elizabeth Sakach; Claire Sathe; Heejoon Ahn; Meghna S. Trivedi; Yelena Novik; Amy Tiersten; George Raptis; Lea Baer; Sun Young Oh; Amelia Zelnak; Kari B. Wisinski; Eleni Andreopoulou; William J. Gradishar; Erica Stringer-Reasor; Sonya Reid; Anne O’Dea; Ruth O’Regan; Katherine D. Crew; Dawn L. Hershman

doi:10.1200/jco.22.02392

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

In this randomized trial, there was a significant PFS benefit for patients with HR+/HER2- MBC who switched ET and received ribociclib compared with placebo after previous CDK4/6i and different ET.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kalinsky et al. (2023) studied this question.

synapsesocial.com/papers/69d8d15017a1cc0598d189fe https://doi.org/10.1200/jco.22.02392

View at Publisher

Ask AI

Bookmark

Share

Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial

Ask about this paper

Abstract

Discussion

Cite This Study

Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading